Default company panoramic image
61c2ff21 c2e3 48d5 acef 1db3195fcaa3

Charisela Technologies

Make assays to measure concentrations of molecules . Are faster, simpler, more accurate and cost 1/2 less than the competitive method.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Menlo Park, CA, USA
  • Currency USD
  • Founded January 2009
  • Employees 3
  • Website

Company Summary

We make assays for flow cytometers that are significantly better than competitive technologies. The assays are faster, simpler, more accurate and cost less than competitors. This is important because we free up resources (people, equip, facilities, dollars) and help researchers doing work in (for e.g.) pancreatic islet transplantation and drug discovery do their jobs better--more efficiently and less expensively


  • Default avatar
    Richard Preston

    Richard has been the CEO of several technology-based companies and is active in the Silicon Valley community. As CEO, he has taken two companies from concept to profitability and sold others to public companies. He has a strong financial and operations background with an MBA from UC Berkeley; public accounting experience with PWC and banking experience as a founder and director of Silicon Valley Bank. He was a Chairman of the American Electronics

  • Default avatar
    Bob Danielzadeh

    Bob has worked for over 20 years in the biotechnology industry in companies such as Syva, Syntex, Becton Dickinson, LJL Biosystems/Molecular Devices, Guava Technologies, and, most recently, Charisela. This provides him with a vast range of experience crucial for insuring development of a successful company in this field. Mr. Danielzadeh’s experience includes: assay development, applications, manufacturing, project leadership, quali

  • Default avatar
    Philip Norris, MD
    Scientific Advisory Board

    is a member of Charisela's Scientific Advisory Board. He is an Adjunct Professor UCSF, Department of Laboratory Medicine; an Associate Director and Associate Investigator, BSRI; Associate Director Clinical Professor, UCSF, Department of Medicine. He received his M.D. degree from Columbia and his B.A and B.S. degrees from UC Berkeley.

  • Default avatar
    Dan Stites, MD
    Chairman, Scientific Advisory Board

    Dan is Chairman of Charisela’s Scientific Advisory Board and an investor in the Company. He was a 30-year member of the UCSF faculty, a Director of the Clinical Immunology Lab at UCSF, and Chairman of the Department of Clinical Pathology with responsibility for its 4 large clinical laboratories. He received his MD degree from Stanford University.

  • Default avatar
    Phil Otto
    Board of Directors

    Phil is a member of the Board of Directors and an investor in the Company. Phil has been CEO and on the Boards of numerous public and private companies including California Microwave, General Cellular, and Optical Communication Products. He has also been a strategic and financial consultant for companies in several technology-oriented industries. Phil has a Harvard MBA and an undergraduate degree in engineering from Yale University.

  • Default avatar
    Bill Hyun PhD
    Scientific Advisory Board

    UCSF Helen Diller Family Comprehensive Cancer Center. For more than two decades he has been director of The Lab for Cell Analysis at the University of California, San Francisco, where he has authored over 100 peer-reviewed publications and issued four scientific technology patents. He holds degrees in Chemistry and Biochemistry from The George Washington University of Washington, D.C.

  • Default avatar
    Matthias Hebrok
    Scientific Advisory Board

    Matthias Hebrok, PhD.
    is the Hurlbut-Johnson Distinguished Professor in Diabetes Research and Director of the UCSF Diabetes Center. He is the recipient of several honors and awards, including the JDRF Scholar Award. He received his Diploma degree in cellular biology from Albert-Ludwigs University in Freiburg, Germany, and performed his PhD thesis at the Max-Planck-Institute for Immunobiology. His postdoctoral research was performed at HHMI at Ha


  • Default avatar
    Casey McGlynn, Wilsom Sonsini
    Default avatar
    Vicky Hamlin

Previous Investors

  • Default avatar
    100% individual angels Angels